Insight

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni Leone/Linkedin

Oct 20, 2024, 13:01

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni LeoneChelsea and Westminster Hospital NHS Foundation Trust, shared a post on LinkedIn about his recent paper published in ESMO Open:

“In PD-L1 ‘low’ HER-2 negative gastroesophageal adenocarcinoma, the benefit of first-line ICI is modest.

Alternative therapeutic options such as zolbetuximab in Claudin18.2-positive disease must be taken into account.”

“Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups”

Authors: Alberto Giovanni Leone, Khi Yung Fong, Elizabeth Smyth, Joseph Zhao, Filippo Pietrantonio et al.

Alberto Giovanni Leone: Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma

Alberto Giovanni Leone is an HIV/Oncology Fellow at Chelsea and Westminster Hospital NHS Foundation Trust. He also serves as a Medical Oncology Resident at the IRCCS Foundation National Cancer Institute of Milan.

Alberto Giovanni Leone cancer Elizabeth Smyth ESMO Open Filippo Pietrantonio gastroesophageal adenocarcinoma Joseph Zhao Khi Yung Fong OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage